Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 20/20 | 0.55 |
| ▸ | CDK2 | P24941 | 20/20 | 0.55 |
| ▸ | CCNA1 | P78396 | 14/20 | 0.55 |
| ▸ | AURKA | O14965 | 7/20 | 0.55 |
| ▸ | CDK4 | P11802 | 8/20 | 0.49 |
| ▸ | CCND3 | P30281 | 8/20 | 0.49 |
| ▸ | CDK6 | Q00534 | 7/20 | 0.49 |
| ▸ | PLK1 | P53350 | 5/20 | 0.49 |
| ▸ | PLK3 | Q9H4B4 | 2/20 | 0.48 |
| ▸ | PLK2 | Q9NYY3 | 2/20 | 0.48 |
| ▸ | TTK | P33981 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3504344 | 0.86 | CCNA2 (0.64) | CCNA2CDK2CCNA1AURKACDK4 | |
| SCHEMBL3503029 | 0.85 | CCNA2 (0.51) | CCNA2CDK2CCNA1AURKACDK4 | |
| SCHEMBL3503045 | 0.85 | CCNA2 (0.64) | CCNA2CDK2CCNA1AURKACDK4 | |
| SCHEMBL18539410 | 0.85 | CCNA2 (0.60) | CCNA2CDK2CCNA1AURKACDK4 | |
| Potassium Ion SCHEMBL3502441 | 0.84 | CCNA2 (0.50) | CCNA2CDK2CCNA1AURKACDK4 | |
| SCHEMBL3503747 | 0.83 | CDK2 (0.66) | CCNA2CDK2CCNA1AURKACDK4 | |
| SCHEMBL1559150 | 0.81 | CCNA2 (0.66) | CCNA2CDK2CCNA1AURKACDK4 | |
| SCHEMBL12499970 | 0.80 | CCNA2 (0.55) | CCNA2CDK2CCNA1AURKACDK4 | |
| SCHEMBL1897199 | 0.76 | TTK (0.73) | CCNA2CDK2CCNA1AURKACDK4 | |
| SCHEMBL12698317 | 0.74 | CCNA2 (0.59) | CCNA2CDK2CCNA1AURKACDK4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10280176-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2019-05-07 | — | — | US | disclosed |
| US-20170190714-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | NERVIANO MEDICAL SCIENCES S.R.L. (IT) | 2017-07-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10280176-B2 | Pyrazolo-quinazoline derivatives, process for their preparation and their use as kinase inhibitors | MAP3K5, MAP3K9, MAP4K2 | CCNA2 1217/4885CDK2 52/4885CCNA1 957/4885 |
| US-20170190714-A1 | PYRAZOLO-QUINAZOLINE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE AS KINASE INHIBITORS | MAP3K5, MAP3K9, MAP4K2 | CCNA2 1217/4885CDK2 52/4885CCNA1 957/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.